WSTWest Pharmaceutical Services
$366.17+44% 1Y
$366.17
$230.7852 weeks$376.78
The financials
West Pharmaceutical Services by the numbers
West Pharmaceutical Services (WST) reported revenue of $872M in Q2 2026 (quarter ended Jun 30, 2026), up 14% from the same quarter a year earlier. That came with a gross margin of 38% and net income of $154M (18% of revenue). For the full year FY2025, revenue was $3.07B (+6.3% year on year) and net income $494M. Its largest segment in Q2 2026 was Proprietary Products at $723M, 83% of the disclosed total, well ahead of West Vantage at 17%. The next results filing is expected around Oct 22, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $872M | $767M | +14% |
| Gross profit | $329M | $274M | +20% |
| Operating income | $179M | $154M | +17% |
| Net income | $154M | $132M | +17% |
| Diluted EPS | $2.15 | $1.82 | +18% |
| Operating | Revenue | Share |
|---|---|---|
| Proprietary Products | $723M | 83% |
| West Vantage | $150M | 17% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $872.3M (+3.2%)
Proprietary Products grew +17% year on yearWest Vantage +2.0% year on year
Segment Latestquarter on quarteryear on year
- Proprietary Products$722.6M$722.6Mquarter on quarter +4.1%year on year +17%+4.1%+17%
- West Vantage$149.7M$149.7Mquarter on quarter -0.60%year on year +2.0%-0.60%+2.0%
On our screens:Stocks with no debt
Medical Instruments & Supplies
The closest names by size in the same industry